article thumbnail

Advancing real-world evidence for pharmaceutical companies in Japan

McKinsey and Company

Insights on Life Sciences Pharmaceuticals JapanPharma companies in Japan have an opportunity to obtain value from real-world evidence using advanced analytics and to better ensure patient outcomes.

article thumbnail

Developing pharmaceutical launch leaders and company-wide capabilities at scale

McKinsey and Company

Insights on Life Sciences PharmaceuticalsBy building certain functional and leadership skills, pharma companies can not only improve the odds of a successful launch but also strengthen their organizations for the future.

professionals

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Veterinary Pharmaceutical Traditional Call Center Models: MOOve Over

Perficient Digital Transformation

Even without its projected growth, animal health organizations, much like their human pharmaceutical counterparts, often do not have the adequate technology infrastructure to support or streamline their call centers.

article thumbnail

Use Cases for Digital Compliance Management in the Pharmaceutical Industry | Market Insights™

Everest Group

Digital Compliance VIEW THE FULL REPORT Business Process Services Digital Services Life Sciences Industry Market Insights™ Procurement / Supply Chain BPO digital life sciences SVM

article thumbnail

How a Fortune 500 Global Pharmaceutical firm setup their AI/ML GCoE in India

Zinnov

A major US pharma company with a global workforce of over 11,000 people across 3 continents wanted to expand their capabilities by building a   Center of Excellence (COE)  in the Machine learning & Artificial Intelligence domain.

article thumbnail

Meeting changing consumer needs: The US retail pharmacy of the future

McKinsey and Company

Insights on Healthcare Systems & Services Health Care Pharmaceuticals Health care providers United StatesIn the face of industry headwinds, pharmacies can work to make the most of their distinct advantages to meet shifting consumer needs.

Retail 113
article thumbnail

The health benefits and business potential of digital therapeutics

McKinsey and Company

Insights on Life Sciences PharmaceuticalsDigital-native start-ups and healthcare incumbents can both play important roles in building and scaling digital therapeutics to improve the management of chronic health conditions.

article thumbnail

Fast to first-in-human: Getting new medicines to patients more quickly

McKinsey and Company

Insights on Life Sciences Pharmaceuticals InnovationPreclinical development can benefit from advances to accelerate innovation, unlock value, and improve quality.

article thumbnail

Health equity: A framework for the epidemiology of care

McKinsey and Company

Pharmaceutical and life sciences companies can unlock new opportunities, help underserved patients, and build a cycle of trust. Insights on Life Sciences Health care reform Pharmaceuticals

article thumbnail

The race to create a vaccine: A conversation with Frank D’Amelio

McKinsey and Company

The CFO of the pharmaceutical company talks about what it took to develop a COVID-19 vaccine. Strategy & Corporate Finance Insights Pharmaceuticals Strategy & Corporate Finance Strategy

article thumbnail

Top ten observations from 2022 in life sciences digital and analytics

McKinsey and Company

Insights on Life Sciences Pharmaceuticals DigitalLife sciences companies are making progress in adopting and deploying digital and analytics. But they can go further and faster by heeding some lessons from the past few years.

Analytics 111
article thumbnail

Upgrading medtech commercial operations in China

McKinsey and Company

Insights on Life Sciences Pharmaceuticals Medical productsGrowth in China’s buoyant medtech market is tapering as policy uncertainties persist. Five approaches to refocus commercial operations can help navigate these challenges.

article thumbnail

Developing a customer-centric approach to rare conditions

McKinsey and Company

Roche Pharmaceuticals’ approach to rare conditions highlights industry efforts to make a difference for patients, their caregivers, and healthcare professionals. Insights on Life Sciences Pharmaceuticals Medical products

article thumbnail

Real-world data quality: What are the opportunities and challenges?

McKinsey and Company

Insights on Life Sciences PharmaceuticalsGrowth in the availability and variety of real-world data, including nonhealth sources of data, opens up new opportunities, as well as challenges, in their application to real-world evidence and improving health outcomes.

Sourcing 106
article thumbnail

A new operating model for pharma: How the pandemic has influenced priorities

McKinsey and Company

Insights on Life Sciences PharmaceuticalsThe COVID-19 pandemic has prompted pharma companies to rethink their organizational strategies. A survey of executives suggests where value might lie.

article thumbnail

Building greater resilience in vaccine manufacturing

McKinsey and Company

Public & Social Sector Insights Public health Public & Social Sector Pharmaceuticals Europe North and Central AmericaThe COVID-19 pandemic has highlighted the need for resilience in vaccine manufacturing. Five considerations can help national public-health leaders plan.

article thumbnail

Four ways pharma companies can make their supply chains more resilient

McKinsey and Company

Pharmaceutical supply chains have become global and complex. Insights on Life Sciences Pharmaceuticals Supply chain managementWith more outsourcing, new modalities, and novel ways to reach patients, it’s critical to ensure that they can withstand shocks.

article thumbnail

How medtechs can meet industry demand for omnichannel engagement

McKinsey and Company

Insights on Life Sciences PharmaceuticalsA McKinsey survey of more than 1,900 medtech leaders shows that their customers want more omnichannel engagement. We describe five ways medtech companies can respond.

article thumbnail

Women in healthcare and life sciences: The ongoing stress of COVID-19

McKinsey and Company

Insights on Healthcare Systems & Services Health care providers PharmaceuticalsThe healthcare sector is examining how to better hire and promote women to the highest levels.

article thumbnail

How Daiichi Sankyo Europe drives growth with digital and analytics

McKinsey and Company

Insights on Life Sciences Pharmaceuticals Digital strategy and organizationDigital and analytics can markedly improve life sciences companies’ engagement with customers.

Analytics 114
article thumbnail

Five ways that life science companies can build tech talent

McKinsey and Company

Insights on Life Sciences Health Care Pharmaceuticals DigitalFor life science companies to meet their digital ambitions, they must strengthen their technology skills. In a challenging market, emphasizing value propositions can attract first-rate talent.

Marketing 126
article thumbnail

The Helix report: Is biopharma wired for future success?

McKinsey and Company

Insights on Life Sciences Health Care PharmaceuticalsThe biopharmaceutical industry has made remarkable achievements in the past decade, but is it equipped to leap still further ahead in the coming one? Company leaders’ answers to nine questions could prove decisive.

article thumbnail

Embedding ‘smart quality’ culture and capabilities in the organization

McKinsey and Company

Pharmaceutical and medical-device companies can get the most value from “smart quality” processes enabled with new technologies by adopting a holistic approach to building culture and capabilities. Insights on Life Sciences Pharmaceuticals Leadership Strategy

article thumbnail

Against the odds: How life sciences companies excel in large transformations

McKinsey and Company

Insights on Life Sciences Pharmaceuticals Performance transformationLife sciences companies pursuing a step change in performance have obtained mixed results. Adhering to five principles can greatly improve the odds of a large transformation program succeeding.

article thumbnail

How sterile pharma manufacturers can grow capacity without capital investment

McKinsey and Company

Insights on Life Sciences PharmaceuticalsThe world will need more sterile products than manufacturers have or can build capacity for. But they can create capacity and take market share by running higher volumes through their existing lines.

article thumbnail

Generating real-world evidence at scale using advanced analytics

McKinsey and Company

Insights on Life Sciences Pharmaceuticals AnalyticsAs pharma companies apply advanced analytics to generate new types of evidence, how do they decide which use cases to target and how to scale them up across the business?

Analytics 129
article thumbnail

Europe’s Bio Revolution: Biological innovations for complex problems

McKinsey and Company

Insights on Life Sciences Health care services Pharmaceuticals Europe Climate changeAdvances in biological science could help the world overcome its most pressing challenges in health and sustainability. Europe’s Bio Revolution could translate scientific strengths into impact.

article thumbnail

Better data for better therapies: The case for building health data platforms

McKinsey and Company

Insights on Life Sciences Health care services Health Care PharmaceuticalsHealth data platforms that participants trust could bring an end to today’s reductionist approach to drug development, revolutionizing our understanding of disease.

article thumbnail

Out of the shadows: A brighter future for pharma technical development

McKinsey and Company

Insights on Life Sciences Pharmaceuticals InnovationThe sometimes-overlooked function of chemistry, manufacturing, and controls (CMC) has a rare opportunity to reimagine its role and find innovative ways to improve and accelerate drug development.

article thumbnail

Resilience in life sciences: Emerging stronger from the downturn

McKinsey and Company

Insights on Life Sciences Medical products PharmaceuticalsAs the life sciences industry is tested by an uncertain economic environment, companies can focus not only on resilience but on positioning themselves to accelerate when coming out of the downturn.

article thumbnail

Pursuing quantum in pharma with purpose: An interview with Boehringer Ingelheim’s CTO

McKinsey and Company

Digital Insights Pharmaceuticals Disruptive Technology Analytics DigitalClemens Utschig-Utschig discusses how his company is exploring quantum computing for its potential to propel next-generation drug discovery.

article thumbnail

Making the leap from R&D to fully integrated biotech for first launch

McKinsey and Company

Insights on Life Sciences Pharmaceuticals Performance transformationMany biotechs struggle with growing pains as they near their first product launch. The transition to commercial success may require shifts in organization, processes, capabilities, and mindsets.

article thumbnail

Getting strategic about new-product submissions in the pharma industry

McKinsey and Company

Insights on Life Sciences PharmaceuticalsBy rethinking the approach to regulatory submissions, pharma companies can reduce timelines and increase their chances of successful product approvals.

article thumbnail

Vision 2028: How China could impact the global biopharma industry

McKinsey and Company

Insights on Life Sciences PharmaceuticalsChina-originated biopharmas will likely have greater influence on the industry by 2028, but regulatory developments and the quality of partnerships will determine how the industry grows.

article thumbnail

How digital helps a life sciences leader move at light speed

McKinsey and Company

Insights on Life Sciences PharmaceuticalsPfizer’s Chief Digital and Technology Officer explains how digital is transforming her organization’s ability to bring new medicines to patients at speed and at scale.

article thumbnail

Innovation sourcing in biopharma: Four practices to maximize success

McKinsey and Company

Insights on Life Sciences Pharmaceuticals Biotechnology Artificial IntelligenceBiopharma companies’ pipelines are full of assets they source externally to access innovation. Four practices will help ensure their investments flourish at a time of fierce competition.

Sourcing 108
article thumbnail

Clinical supply chains: How to boost excellence and innovation

McKinsey and Company

Insights on Life Sciences Pharmaceuticals Supply chain managementClinical trials have increased in number and have become more complex, decentralized, and patient-centric. While this puts pressure on clinical drug supply, it also brings new opportunities.

article thumbnail

Emerging from disruption: The future of pharma operations strategy

McKinsey and Company

Insights on Operations Pharmaceuticals Operations strategy Manufacturing operationsTo maintain profitable and resilient operations, CEOs and COOs of pharma companies may need to make bold changes to their operations strategy as the industry navigates new challenges.

article thumbnail

Comment on Paying Doctors and Nurses – Can be a GOOD Thing #Change My Mind by Pharmaceutical Marketing - Where Do We Draw The Line?

Ms Category Management

[…] you may know from one of my blogs, “Why Paying Doctors and Nurses Good Thing,” I am in support of the marketing efforts we have for Physicians. Because in short, if […

article thumbnail

AI in biopharma research: A time to focus and scale

McKinsey and Company

Insights on Life Sciences PharmaceuticalsBy focusing on specific scientific and operational pain points and fully integrating AI into research workflows, biopharma companies can deliver greater patient impact and significant value.

article thumbnail

The dawn of China biopharma innovation

McKinsey and Company

Insights on Life Sciences Pharmaceuticals Medical products ChinaChinese biopharma is making a mark on the global stage as the rapidly evolving regulatory landscape and maturing innovation ecosystem spur significant value creation.

article thumbnail

Integrated evidence generation: A paradigm shift in biopharma

McKinsey and Company

Insights on Life Sciences Medical products PharmaceuticalsBiopharma companies should consider a new, integrated approach to evidence-generation strategies to better demonstrate the value of therapies to all stakeholders.

article thumbnail

Viral-vector therapies at scale: Today’s challenges and future opportunities

McKinsey and Company

Insights on Life Sciences PharmaceuticalsViral-vector gene therapies are here to stay. Keeping pace with increasing demand requires consideration of challenges, the potential for standardization, and strategizing for accelerating patient access.